Gama Ntombenhle, Kumar Kamlesh, Ekengard Erik, Haukka Matti, Darkwa James, Nordlander Ebbe, Meyer Debra
Department of Biochemistry, University of Pretoria, Hatfield Campus, Pretoria, 0002, South Africa.
Inorganic Chemistry Research Group, Chemical Physics, Center for Chemistry and Chemical Engineering, Lund University, Box 124, 22100, Lund, Sweden.
Biometals. 2016 Jun;29(3):389-97. doi: 10.1007/s10534-016-9921-9. Epub 2016 Feb 27.
HIV infection is known for replicating in proliferating CD(+) T-cells. Treatment of these cells with cytostatic (anti-proliferation) compounds such as hydroxyurea interferes with the cells's ability support HIV replication. Combinations of such cytostatic compounds with proven anti-retroviral drugs (like ddI) are known as virostatic, and have been shown to aid in the control of the infection. The use of two different drugs in virostatic combinations however, carries the risk of adverse effects including drug-drug interactions, which could lead to augmented toxicities and reduced efficacy. Here, a novel digold(I) complex of ferrocene-quinoline (3) was investigated for cytostatic behaviour as well as anti-viral activity which if demonstrated would eliminate concerns of drug-drug interactions. The complex was synthesized and characterized by NMR, FT-IR and mass spectroscopy and the molecular structure was confirmed by X-ray crystallography. Bio-screening involved viability dyes, real time electronic sensing and whole virus assays. The complex showed significant (p = 0.0092) inhibition of virus infectivity (83 %) at 10 ug/mL. This same concentration caused cytostatic behaviour in TZM-bl cells with significant (p < 0.01) S and G2/M phase cell cycle arrest. These data supports 3 as a virostatic agent, possessing both anti-viral and cytostatic characteristics. In the absence of 3, TZM-bl cells were infected by a pseudovirus and this was demonstrated through luminescence in a luciferase assay. Pre-incubation of the virus with 3 decreased luminescence, indicating the anti-viral activity of 3. Complex 3 also showed cytostatic behavior with increased S-phase and G2/M phase cell cycle arrest.
HIV感染以在增殖的CD(+) T细胞中复制而闻名。用细胞生长抑制剂(抗增殖)化合物如羟基脲处理这些细胞会干扰细胞支持HIV复制的能力。这种细胞生长抑制剂化合物与已证实的抗逆转录病毒药物(如双脱氧肌苷)的组合被称为病毒生长抑制剂,并且已显示有助于控制感染。然而,在病毒生长抑制剂组合中使用两种不同的药物存在不良反应的风险,包括药物相互作用,这可能导致毒性增加和疗效降低。在此,研究了一种新型的二茂铁 - 喹啉二金(I)配合物(3)的细胞生长抑制行为以及抗病毒活性,如果得到证实,将消除对药物相互作用的担忧。该配合物通过核磁共振、傅里叶变换红外光谱和质谱进行了合成和表征,其分子结构通过X射线晶体学得到确认。生物筛选涉及活力染料、实时电子传感和全病毒检测。该配合物在10μg/mL时对病毒感染性表现出显著(p = 0.0092)抑制(83%)。相同浓度在TZM-bl细胞中引起细胞生长抑制行为,伴有显著(p < 0.01)的S期和G2/M期细胞周期停滞。这些数据支持3作为一种病毒生长抑制剂,具有抗病毒和细胞生长抑制特性。在没有3的情况下,TZM-bl细胞被假病毒感染,这在荧光素酶检测中通过发光得到证实。病毒与3预孵育会降低发光,表明3具有抗病毒活性。配合物3还表现出细胞生长抑制行为,伴有S期和G2/M期细胞周期停滞增加。